DV
Dividend Vision

SCLX — Scilex Holding Company

Scilex Holding Company (SCLX)

Total return is -96.9% over the past 5.4 years, 214.8 points behind SPY at 117.9%. Its deepest 1-year drawdown was 80.3%.

Scilex Holding Company is a pharmaceutical company focused on acquiring, developing, and commercializing non-opioid pain management products, with commercial offerings including ZTlido (a prescription lidocaine topical system for neuropathic pain), ELYXYB (an oral solution for acute migraine treatment), and GLOPERBA (an oral colchicine formulation for gout prophylaxis), along with three product candidates in clinical development. The company does not currently distribute dividends. Scilex appeals primarily to investors seeking exposure to specialized pharmaceutical development rather than current income generation.

SCLX key facts

Asset type
Stock
Asset class
Equity
Inception date
03/05/2021
Last close
$6.76
Market cap
$53,732,156
Average volume
27963.0
Beta
1.727
Payout ratio
0.0
Forward P/E
2.6624
EPS
$-36.83